Adage Capital Partners
TVTX icon

Adage Capital Partners’s Travere Therapeutics TVTX Stock Holding History

Adage Capital Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146M Buy
2,569,356
+1,592,356
+163% +$70.6M 0.2% 85
2026
Q1 		$29M Sell
977,000
-1,950,000
-67% -$58.3M 0.04% 377
2025
Q4 		$112M Sell
2,927,000
-625,000
-18% -$20.3M 0.17% 115
2025
Q3 		$84.9M Buy
3,552,000
+768,000
+28% +$14.4M 0.13% 154
2025
Q2 		$41.2M Buy
2,784,000
+599,102
+27% +$9.93M 0.07% 279
2025
Q1 		$39.2M Buy
2,184,898
+1,808,098
+480% +$36.7M 0.07% 281
2024
Q4 		$6.56M Sell
376,800
-23,200
-6% -$410K 0.01% 681
2024
Q3 		$5.6M Hold
400,000
– – 0.01% 704
2024
Q2 		$3.29M Sell
400,000
-100,000
-20% -$673K 0.01% 749
2024
Q1 		$3.85M Hold
500,000
– – 0.01% 723
2023
Q4 		$4.5M Buy
+500,000
New +$3.64M 0.01% 690
2023
Q2 		– Sell
-4,113,962
Closed -$92.5M – 931
2023
Q1 		$92.5M Buy
4,113,962
+1,513,962
+58% +$32.2M 0.21% 116
2022
Q4 		$54.7M Buy
2,600,000
+250,000
+11% +$5.3M 0.13% 190
2022
Q3 		$57.9M Buy
2,350,000
+400,000
+21% +$10.3M 0.14% 162
2022
Q2 		$47.2M Buy
1,950,000
+447,508
+30% +$11.3M 0.11% 200
2022
Q1 		$38.7M Buy
1,502,492
+200,000
+15% +$5.31M 0.07% 285
2021
Q4 		$40.4M Sell
1,302,492
-397,508
-23% -$11.2M 0.07% 279
2021
Q3 		$41.2M Sell
1,700,000
-1,893,763
-53% -$34.8M 0.08% 250
2021
Q2 		$52.4M Sell
3,593,763
-956,237
-21% -$18.9M 0.1% 205
2021
Q1 		$114M Buy
4,550,000
+1,700,000
+60% +$47M 0.23% 91
2020
Q4 		$77.7M Buy
2,850,000
+1,315,500
+86% +$30.7M 0.17% 131
2020
Q3 		$28.3M Sell
1,534,500
-100,000
-6% -$1.94M 0.07% 293
2020
Q2 		$33.4M Buy
1,634,500
+592,702
+57% +$9.44M 0.09% 266
2020
Q1 		$15.2M Buy
1,041,798
+966,798
+1,289% +$14.5M 0.05% 384
2019
Q4 		$1.06M Sell
75,000
-25,000
-25% -$319K ﹤0.01% 679
2019
Q3 		$1.16M Buy
+100,000
New +$1.65M ﹤0.01% 678

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners's TVTX Position: Q2 2026 in Review

Adage Capital Partners increased its Travere Therapeutics (TVTX) stake by 163% in Q2 2026, buying an estimated $70.6M and bringing the position to 2,569,356 shares worth $146M. The position accounts for 0.2% of the portfolio, ranked #85.

Adage Capital Partners first reported a position in TVTX in Q3 2019 and has held it in 26 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Adage Capital Partners held 2,569,356 shares of Travere Therapeutics worth $146M as of Q2 2026.
  • Adage Capital Partners bought 1,592,356 Travere Therapeutics shares in Q2 2026, an estimated $70.6M.
  • Travere Therapeutics made up 0.2% of Adage Capital Partners's portfolio in Q2 2026, its #85 holding.
  • Adage Capital Partners first reported a position in Travere Therapeutics in Q3 2019 and has held it in 26 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.